AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plc (LON: AZN) said on Friday that its sales and earnings posted an increase in the first quarter and reiterated its guidance for the full financial year. The pharmaceutical firm also expressed confidence that the impact of COVID-19 was likely to tone down in the second half.

AstraZeneca's net profit jumps to £1.12 billion in the first quarter

LONDON (Reuters) -AstraZeneca Chief Executive Pascal Soriot said on Friday the drugmaker had not overpromised on the supply of COVID-19 vaccines around the world, as he defended big cuts in deliveries that prompted a lawsuit by the European Union.

AstraZeneca's Soriot: we didn't overpromise on COVID-19 vaccine supplies

AstraZeneca said on Friday its COVID-19 vaccine contributed $275 million in sales and shaved three cents per share from its first-quarter earnings.

Trials and tribulations of AstraZeneca's COVID-19 vaccine

AstraZeneca PLC (LON:AZN) expects the impact of the pandemic to reduce, leading to a performance boost in the second half of 2021. Chief executive Pascal Soriot reiterated guidance after first-quarter figures were in line with expectations.

AstraZeneca expects performance boost in second half after posting 15% quarterly revenue jump

AstraZeneca said on Friday it expected higher sales in the second half of the year, as it reported first-quarter profit and sales ahead of analysts' average expectations, including $275 million in COVID-19 vaccine sales.

AstraZeneca expects higher H2 sales as Q1 sales, earnings beat forecasts

AbbVie

Merck

In my April 27 discussion, I looked at the pharmaceutical companies that are most likely to pursue acquisitions this year, with activity forecasted to pick up after a down 2020. While the pandemic contributed to the slowdown in merger and acquisitions, licensing arrangements fared far better, coming in relatively flat at a total value of about $40 billion

AstraZeneca, Merck, AbbVie Struck Biggest Licensing Deals in 2020

It has been hard to keep AstraZeneca PLC (LON:AZN) out of the news and it will get further attention on Friday when it releases a first-quarter trading update. UBS is forecasting total revenues of US$7.07bn, which puts it above the consensus forecast of US$6.95bn.

AstraZeneca to show there is more to the company than the COVID-19 vaccine

Chevron

Exxon Mobil

Yet another look at some of the more than 900 publicly traded companies scheduled to report March quarter earnings this week.

Earnings Previews: AbbVie, AstraZeneca, Chevron, Exxon

The European Commission, the EU's executive body, accuses AstraZeneca of failing to abide by its contract to deliver 300 million vaccine doses by the end of June,

EU legal complaint against AstraZeneca heard in Brussels court

In Wednesday's UK coronavirus news, a new study by Public Health England (PHE) has shown that one dose of a vaccine reduces household transmission by up to half. Researchers studied 57,000 contacts from 24,000 households where a person who had received the jab contracted the virus.

Coronavirus: One vaccine dose enough to cut transmission risk by half, AstraZeneca/EU legal challenge begins

Public preference for the AstraZeneca vaccine has fallen since reports potentially linking it to some cases of unusual blood clotting cases, a U.K. study shows.

Public demand for AstraZeneca vaccine falls in Britain after blood clot scares

Amgen

Bristol-Myers

Gilead Sciences

Johnson & Johnson

Companies likely seeking bolt-on acquisitions, not mega-deals

Top Pharma Giants Expected to Be Most Active in M&A

AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.

Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?

The United States will start to share up to 60 million doses of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine doses with other countries as they become available, White House senior COVID-19 adviser Andy Slavitt said on Monday. “The U.S. to release 60 million AstraZeneca doses to other countries as they become available,” he wrote on Twitter.

US To Share Up To 60M AstraZeneca COVID-19 Vaccine Doses

Pfizer

U.S. Trade Representative Katherine Tai on Monday met virtually with top executives of drugmakers Pfizer and AstraZeneca PLC to discuss a proposed waiver of certain intellectual property rights in response to the COVID-19 pandemic.

Top U.S. trade negotiator meets Pfizer, AstraZeneca execs on COVID-19 IP waiver

10 million of that total could ship out within weeks.

U.S. Will Export up to 60 Million Doses of AstraZeneca Coronavirus Vaccine

The US will share up to 60 million doses of the AstraZeneca vaccine with the world, the White House has said.

US to share up to 60 million doses of AstraZeneca vaccine with the world

The European Union said Monday it is suing AstraZeneca over an alleged breach of its vaccine supply contract, a dramatic escalation of a months-long dispute over delivery delays that hampered the rollout of shots across the continent.

EU sues AstraZeneca after delays in vaccine deliveries

Covid-19 cases continue to spike worldwide as countries push to vaccinate more people.

U.S. to share 60 million doses of AstraZeneca Covid vaccine with other countries

Last week the European Commission was weighing legal action against AstraZeneca Plc (NASDAQ: AZN) over its COVID-19 vaccine delivery delays. Today, the Commission confirmed that it had taken legal action against the company for failing to deliver its promised supply of COVID-19 vaccines and not have a “reliable” plan to ensure timely deliveries, a spokesperson told Reuters.

European Union Files Lawsuit Against AstraZeneca Over COVID-19 Vaccine Shortfall

The U.S. will share the stockpiled AstraZeneca doses with other nations once the coronavirus vaccine is cleared by federal safety regulators.

U.S. To Share Up To 60 Million AstraZeneca Vaccine Doses With Other Nations

The company said it has experienced “manufacturing challenges” but denied wrongdoing for the shortfall in promised doses.

AstraZeneca Sued By EU's Executive Branch Over Covid Vaccine Delivery Delays

AstraZeneca PLC (LON:AZN) has been sued by the EU Commission over COVID-19 vaccine deliveries, it has emerged. All 27 states backed the legal challenge, which started last Friday.

AstraZeneca sued by EU Commission over COVID-19 vaccine deliveries

AstraZeneca faces suit by European Commission over vaccine deliveries

The European Union confirmed Monday its taking legal action against AstraZeneca over shortfalls in the deliveries of its coronavirus vaccine.

News for AstraZeneca Stock (AZN)